Montelukast Sodium

Global Montelukast Sodium Market to Reach US$1.1 Billion by 2030

The global market for Montelukast Sodium estimated at US$504.7 Million in the year 2024, is expected to reach US$1.1 Billion by 2030, growing at a CAGR of 14.1% over the analysis period 2024-2030. Tablets Form, one of the segments analyzed in the report, is expected to record a 12.5% CAGR and reach US$615.5 Million by the end of the analysis period. Growth in the Oral Solutions segment is estimated at 16.5% CAGR over the analysis period.

The U.S. Market is Estimated at US$137.5 Million While China is Forecast to Grow at 18.6% CAGR

The Montelukast Sodium market in the U.S. is estimated at US$137.5 Million in the year 2024. China, the world`s second largest economy, is forecast to reach a projected market size of US$235.8 Million by the year 2030 trailing a CAGR of 18.6% over the analysis period 2024-2030. Among the other noteworthy geographic markets are Japan and Canada, each forecast to grow at a CAGR of 10.6% and 12.5% respectively over the analysis period. Within Europe, Germany is forecast to grow at approximately 11.2% CAGR.

Global Montelukast Sodium Market – Key Trends & Drivers Summarized

Why Is Montelukast Sodium Gaining Widespread Adoption in Respiratory Disease Treatment?

Montelukast sodium has become a widely prescribed pharmaceutical for managing respiratory conditions such as asthma, allergic rhinitis, and exercise-induced bronchoconstriction. As a leukotriene receptor antagonist (LTRA), montelukast works by blocking inflammatory pathways that contribute to airway constriction, making it an effective long-term therapy for asthma management. With the increasing prevalence of chronic respiratory diseases due to pollution, climate change, and lifestyle factors, the demand for montelukast sodium has surged globally. Unlike corticosteroids, montelukast is preferred by many patients due to its oral administration, fewer side effects, and suitability for pediatric use. Additionally, the rise in seasonal allergies and air pollution-related respiratory issues has expanded the use of montelukast in both prescription and over-the-counter formulations.

What Advancements in Pharmaceutical Formulations Are Enhancing Montelukast Sodium`s Market Potential?

The pharmaceutical industry has witnessed significant advancements in the formulation and delivery of montelukast sodium, improving its bioavailability and therapeutic efficacy. The development of chewable tablets and oral granules has made it easier for pediatric and geriatric patients to adhere to treatment regimens. Additionally, combination therapies incorporating montelukast with antihistamines, such as levocetirizine, have gained popularity for their dual-action benefits in managing both allergic and respiratory symptoms. Novel drug delivery mechanisms, including controlled-release formulations, are also being explored to improve patient compliance and prolong therapeutic effects. The shift toward personalized medicine has further driven research into genetic factors influencing montelukast response, paving the way for more targeted and effective treatments. As pharmaceutical companies continue to invest in innovative drug formulations, the accessibility and usability of montelukast sodium are expected to improve.

How Is the Rising Burden of Respiratory Diseases Shaping Market Demand?

The increasing global incidence of asthma, chronic obstructive pulmonary disease (COPD), and allergic conditions has created a substantial demand for effective respiratory therapies, boosting the montelukast sodium market. Urbanization and industrialization have led to rising levels of air pollution, a key trigger for respiratory conditions. Additionally, the growing geriatric population, which is more prone to respiratory diseases, has contributed to market expansion. Healthcare providers are increasingly recommending montelukast as an adjunct therapy alongside inhaled corticosteroids for better asthma management. The COVID-19 pandemic has also played a role in shifting attention toward respiratory health, increasing awareness and diagnosis rates for chronic respiratory conditions. Furthermore, patient preference for non-invasive, oral treatments over inhaled medications has bolstered the adoption of montelukast sodium as a first-line therapy in several regions.

What Are the Key Factors Driving Growth in the Montelukast Sodium Market?

The growth in the montelukast sodium market is driven by several factors, including the rising prevalence of respiratory diseases, expanding pharmaceutical innovations, and increasing awareness about allergic conditions. The demand for cost-effective and easily accessible asthma treatments has propelled the adoption of montelukast across developed and emerging markets. The expansion of generic drug manufacturers has also increased market penetration, making montelukast more affordable and widely available. Additionally, the growing use of combination therapies, where montelukast is paired with antihistamines or corticosteroids, is creating new opportunities for pharmaceutical companies. Government initiatives promoting asthma management programs and increased healthcare spending in emerging economies are further contributing to market growth. The shift toward personalized medicine and research into biomarkers for better treatment outcomes is also expected to enhance the future potential of montelukast sodium. As the global burden of respiratory diseases continues to rise, the montelukast sodium market is set for sustained expansion in the coming years.

SCOPE OF STUDY:

The report analyzes the Montelukast Sodium market in terms of units by the following Segments, and Geographic Regions/Countries:

Segments:
Dosage Form (Tablets Form, Oral Solutions); Application (Asthma Application, Allergic Rhinitis Application, Urticaria Application, Other Applications)

Geographic Regions/Countries:
World; United States; Canada; Japan; China; Europe (France; Germany; Italy; United Kingdom; Spain; Russia; and Rest of Europe); Asia-Pacific (Australia; India; South Korea; and Rest of Asia-Pacific); Latin America (Argentina; Brazil; Mexico; and Rest of Latin America); Middle East (Iran; Israel; Saudi Arabia; United Arab Emirates; and Rest of Middle East); and Africa.

Select Competitors (Total 41 Featured) -

• Aarti Pharmalabs Ltd.
• Apotex Inc.
• Aurobindo Pharma Limited
• Cipla Limited
• Dr. Reddy`s Laboratories
• Hetero Drugs Limited
• Inke S.A.
• Intas Pharmaceuticals Ltd.
• Jai Radhe Sales
• Kimia Biosciences Ltd.
• LGM Pharma
• Merck & Co., Inc.
• Metrochem API Private Limited
• Minakem (formerly Delmar Chemicals)
• Morepen Laboratories Ltd.
• Neuland Laboratories Ltd.
• Sanofi S.A.
• Seqens
• Sun Pharmaceutical Industries Ltd.
• Teva Pharmaceutical Industries Ltd.

TARIFF IMPACT FACTOR

Our new release incorporates impact of tariffs on geographical markets as we predict a shift in competitiveness of companies based on HQ country, manufacturing base, exports and imports (finished goods and OEM). This intricate and multifaceted market reality will impact competitors by artificially increasing the COGS, reducing profitability, reconfiguring supply chains, amongst other micro and macro market dynamics.

We are diligently following expert opinions of leading Chief Economists (14,949), Think Tanks (62), Trade & Industry bodies (171) worldwide, as they assess impact and address new market realities for their ecosystems. Experts and economists from every major country are tracked for their opinions on tariffs and how they will impact their countries.

We expect this chaos to play out over the next 2-3 months and a new world order is established with more clarity. We are tracking these developments on a real time basis.

As we release this report, U.S. Trade Representatives are pushing their counterparts in 183 countries for an early closure to bilateral tariff negotiations. Most of the major trading partners also have initiated trade agreements with other key trading nations, outside of those in the works with the United States. We are tracking such secondary fallouts as supply chains shift.

To our valued clients, we say, we have your back. We will present a simplified market reassessment by incorporating these changes!

APRIL 2025: NEGOTIATION PHASE

Our April release addresses the impact of tariffs on the overall global market and presents market adjustments by geography. Our trajectories are based on historic data and evolving market impacting factors.

JULY 2025 FINAL TARIFF RESET

Complimentary Update: Our clients will also receive a complimentary update in July after a final reset is announced between nations. The final updated version incorporates clearly defined Tariff Impact Analyses.

Reciprocal and Bilateral Trade & Tariff Impact Analyses:

USA
CHINA
MEXICO
CANADA
EU
JAPAN
INDIA
176 OTHER COUNTRIES.

Leading Economists - Our knowledge base tracks 14,949 economists including a select group of most influential Chief Economists of nations, think tanks, trade and industry bodies, big enterprises, and domain experts who are sharing views on the fallout of this unprecedented paradigm shift in the global econometric landscape. Most of our 16,491+ reports have incorporated this two-stage release schedule based on milestones.

Please note: Reports are sold as single-site single-user licenses. Electronic versions require 24-48 hours as each copy is customized to the client with digital controls and custom watermarks. The Publisher uses digital controls protecting against copying and printing is restricted to one full copy to be used at the same location.

The latest version of Adobe Acrobat Reader is required to view the report. Upon ordering an electronic version, the Publisher will provide a link to download the purchased report.

Prior to fulfillment of an order, the client will be required to sign a document detailing the purchase terms for a publication from this publisher.